Barry D. Bertolet, M.D., FACC
Principal Investigator
Roche M & M
A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of R04607381 on Cardiovascular (CV) Risk in Stable Coronary Heart Disease Patients with a Documented Recent Acute Coronary Syndrome (ACS)
Summary: The primary objective of this trial is to evaluate the potential of R04607381 to reduce cardiovascular morbidity and mortality in stable coronary heart disease patients with a documented recent acute coronary syndrome.